Abstract Objective To study the efficacy and safety of rituximab combined with chemotherapy in the treatment of children and adolescents with mature B-cell non-Hodgkin's lymphoma (B-NHL) through a Meta analysis. Methods The databases including PubMed, Embase, the Cochrane Library, ClinicalTrials.gov, Web of Science, China National Knowledge Infrastructure, Wanfang Data, and Weipu were searched to obtain 10 articles on rituximab in the treatment of mature B-NHL in children and adolescents published up to June 2022, with 886 children in total. With 3-year event-free survival (EFS) rate, 3-year overall survival (OS) rate, complete remission rate, mortality rate, and incidence rate of adverse reactions as outcome measures, RevMan 5.4 software was used for Meta analysis, subgroup analysis, sensitivity analysis, and publication bias analysis. Results The rituximab+chemotherapy group showed significant increases in the 3-year EFS rate (HR=0.38, 95%CI: 0.25-0.59, P<0.001), 3-year OS rate (HR=0.29, 95%CI: 0.14-0.61, P=0.001), and complete remission rate (OR=3.72, 95%CI: 1.89-7.33, P<0.001) as well as a significant reduction in the mortality rate (OR=0.31, 95%CI: 0.17-0.57, P<0.001), as compared with the chemotherapy group without rituximab. There was no significant difference in the incidence rate of adverse reactions between the two groups (OR=1.28, 95%CI: 0.85-1.92, P=0.24). Conclusions The addition of rituximab to the treatment regimen for children and adolescents with mature B-cell non-Hodgkin's lymphoma can bring significant survival benefits without increasing the incidence of adverse reactions.
LI Bi-Yun,HAN Ya-Hui,YIN Chu-Yun et al. Efficacy and safety of rituximab in children and adolescents with mature B-cell non-Hodgkin's lymphoma: a Meta analysis[J]. CJCP, 2023, 25(1): 51-59.
LI Bi-Yun,HAN Ya-Hui,YIN Chu-Yun et al. Efficacy and safety of rituximab in children and adolescents with mature B-cell non-Hodgkin's lymphoma: a Meta analysis[J]. CJCP, 2023, 25(1): 51-59.
Harker-Murray PD, Pommert L, Barth MJ. Novel therapies potentially available for pediatric B-cell non-Hodgkin lymphoma[J]. J Natl Compr Canc Netw, 2020, 18(8): 1125-1134. PMID: 32755987. DOI: 10.6004/jnccn.2020.7608.
Egan G, Goldman S, Alexander S. Mature B-NHL in children, adolescents and young adults: current therapeutic approach and emerging treatment strategies[J]. Br J Haematol, 2019, 185(6): 1071-1085. PMID: 30613948. DOI: 10.1111/bjh.15734.
Chiappella A, Martelli M, Angelucci E, et al. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study[J]. Lancet Oncol, 2017, 18(8): 1076-1088. PMID: 28668386. DOI: 10.1016/S1470-2045(17)30444-8.
Rigaud C, Auperin A, Jourdain A, et al. Outcome of relapse in children and adolescents with B-cell non-Hodgkin lymphoma and mature acute leukemia: a report from the French LMB study[J]. Pediatr Blood Cancer, 2019, 66(9): e27873. PMID: 31207026. DOI: 10.1002/pbc.27873.
Sabattini E, Bacci F, Sagramoso C, et al. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview[J]. Pathologica, 2010, 102(3): 83-87. PMID: 21171509.
13 Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions: version 5.1.0[EB/OL]. (2011-03-20)[2020-10-06].
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses[J]. Eur J Epidemiol, 2010, 25(9): 603-605. PMID: 20652370. DOI: 10.1007/s10654-010-9491-z.
Dourthe ME, Phulpin A, Auperin A, et al. Rituximab in addition to LMB-based chemotherapy regimen in children and adolescents with primary mediastinal large B-cell lymphoma: results of the French LMB2001 prospective study[J]. Haematologica, 2022, 107(9): 2173-2182. PMID: 35236054. PMCID: PMC9425314. DOI: 10.3324/haematol.2021.280257.
Fu Y, Wang H, Zhai X, et al. Improved outcome of newly diagnosed childhood mature B-cell lymphoma/leukemia with high tumor burden treated with BFM95-based protocol combining rituximab: a report from Shanghai, China[J]. J Pediatr Hematol Oncol, 2019, 41(3): 170-174. PMID: 30664102. DOI: 10.1097/MPH.0000000000001419.
Huang S, Jin L, Yang J, et al. Treatment outcome in children with central nervous system-positive Burkitt lymphoma using only intrathecal and systemic chemotherapy combined with rituximab[J]. Chin Med J (Engl), 2021, 134(11): 1329-1334. PMID: 33734131. PMCID: PMC8183724. DOI: 10.1097/CM9.0000000000001386.
Zhen Z, Zhu J, Wang J, et al. Rituximab is highly effective in children and adolescents with Burkitt lymphoma in risk groups R2 to R4[J]. Pediatr Hematol Oncol, 2020, 37(6): 489-499. PMID: 32364412. DOI: 10.1080/08880018.2020.1759741.
Barth MJ, Minard-Colin V. Novel targeted therapeutic agents for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma[J]. Br J Haematol, 2019, 185(6): 1111-1124. PMID: 30701541. DOI: 10.1111/bjh.15783.
Giulino-Roth L, Goldman S. Recent molecular and therapeutic advances in B-cell non-Hodgkin lymphoma in children[J]. Br J Haematol, 2016, 173(4): 531-544. PMID: 26996160. DOI: 10.1111/bjh.13969.
Cairo M, Auperin A, Perkins SL, et al. Overall survival of children and adolescents with mature B cell non-Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB/LMB 96: a report from the FAB/LMB 96 study group[J]. Br J Haematol, 2018, 182(6): 859-869. PMID: 29984828. PMCID: PMC6128751. DOI: 10.1111/bjh.15491.
Maschan A, Myakova N, Aleinikova O, et al. Rituximab and reduced-intensity chemotherapy in children and adolescents with mature B-cell lymphoma: interim results for 231 patients enrolled in the second Russian-Belorussian multicentre study B-NHL-2010M[J]. Br J Haematol, 2019, 186(3): 477-483. PMID: 31069789. DOI: 10.1111/bjh.15944.
Srinivasan S, Roy Moulik N, Kc A, et al. Increased toxicities in children with Burkitt lymphoma treated with rituximab: experience from a tertiary cancer center in India[J]. Pediatr Blood Cancer, 2020, 67(11): e28682. PMID: 32865865. DOI: 10.1002/pbc.28682.
36 FDA. FDA approves rituximab plus chemotherapy for pediatric cancer indications[EB/OL]. (2021-12-03)[2022-08-02]. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-rituximab-plus-chemotherapy-pediatric-cancer-indications.
Hayden PJ, Roddie C, Bader P, et al. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)[J]. Ann Oncol, 2022, 33(3): 259-275. PMID: 34923107. DOI: 10.1016/j.annonc.2021.12.003.